Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 44, 2014, Pages 15614-15621

  Lewis, George K ^a   DeVico, Anthony L ^a   Gallo, Robert C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Antibody persistence; HIV; T cell; Vaccine

Indexed keywords

ERDOSTEINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; REVIEW; T LYMPHOCYTE; VIRUS REPLICATION; HIV INFECTIONS; IMMUNOLOGY; PATHOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84914695671     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1413550111     Document Type: Review

References (109)

1. Finzi D, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278(5341): 1295-1300.
2. Chun TW, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387(6629):183-188.
3. Tsai CC, et al. (1998) Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 72(5):4265-4273.
4. Nishimura Y, et al. (2003) Transfer of neutralizing IgG to macaquesh but not 24 h after SHIV infection confers sterilizing protection: Implications for HIV-1 vaccine development. Proc Natl Acad Sci USA 100(25):15131-15136.
5. Ferrantelli F, et al. (2007) Time dependence of protective postexposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. Virology 358(1): 69-78.
6. Foresman L, et al. (1998) Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques. AIDS Res Hum Retroviruses 14(12):1035-1043.
7. Thèze J, Chakrabarti LA, Vingert B, Porichis F, Kaufmann DE (2011) HIV controllers: A multifactorial phenotype of spontaneous viral suppression. Clin Immunol 141(1):15-30.
8. Ranasinghe S, et al. (2012) HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J Virol 86(1):277-283.
9. Soghoian DZ, et al. (2012) HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med 4(123):123ra125.
10. Stanley SK, et al. (1996) Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 334(19):1222-1230.
11. Gilbert PB, et al. (2005) Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191(5):666-677.
12. Pitisuttithum P, et al.; Bangkok Vaccine Evaluation Group (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194(12): 1661-1671.
13. Buchbinder SP, et al.; Step Study Protocol Team (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-ofconcept trial. Lancet 372(9653):1881-1893.
14. Gray GE, et al.; HVTN 503/Phambili study team (2011) Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: A double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 11(7):507-515.
15. Gray GE, et al. (2014) Recombinant adenovirus type 5 HIV gag/ pol/nef vaccine in South Africa: Unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis 14(5): 388-396.
16. Hammer SM, et al.; HVTN 505 Study Team (2013) Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 369(22):2083-2092.
17. Gallo RC (2005) The end or the beginning of the drive to an HIVpreventive vaccine: A view from over 20 years. Lancet 366(9500): 1894-1898.
18. Hansen SG, et al. (2013) Immune clearance of highly pathogenic SIV infection. Nature 502(7469):100-104.
19. Koff WC, et al. (2013) Accelerating next-generation vaccine development for global disease prevention. Science 340(6136): 1232910.
20. Doria-Rose NA, et al.; NISC Comparative Sequencing Program (2014) Developmental pathway for potent V1V2-directed HIVneutralizing antibodies. Nature 509(7498):55-62.
21. Rerks-Ngarm S, et al.; MOPH-TAVEG Investigators (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361(23):2209-2220.
22. Klasse PJ, Sanders RW, Cerutti A, Moore JP (2012) How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses 28(1):1-15.
23. Sundling C, et al. (2013) Immunization of macaques with soluble HIV type 1 and influenza virus envelope glycoproteins results in a similarly rapid contraction of peripheral B-cell responses after boosting. J Infect Dis 207(3):426-431.
24. Gilbert PB, Shepherd BE, Hudgens MG (2013) Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical Trials. J Am Stat Assoc 108(503):789-800.
25. Haynes BF, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366(14):1275-1286.
26. Yates NL, et al. (2014) Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 6(228):228ra239.
27. Gottardo R, et al. (2013) Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS ONE 8(9):e75665.
28. Tomaras GD, et al. (2013) Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci USA 110(22):9019-9024.
29. Zolla-Pazner S, et al. (2014) Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS ONE 9(2):e87572.
30. Robb ML, et al. (2012) Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 12(7):531-537.
31. Perreau M, et al. (2013) Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 210(1):143-156.
32. Xu Y, et al. (2013) Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques. J Virol 87(7):3760-3773.
33. Brenchley JM, et al. (2012) Differential infection patterns of CD4+ T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections. Blood 120(20):4172-4181.
34. Locci M, et al.; International AIDS Vaccine Initiative Protocol C Principal Investigators (2013) Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 39(4):758-769.
35. Gitlin AD, Shulman Z, Nussenzweig MC (2014) Clonal selection in the germinal centre by regulated proliferation and hypermutation. Nature 509(7502):637-640.
36. Klein F, et al. (2013) Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153(1):126-138.
37. Keele BF, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 105(21):7552-7557.
38. Lu KT, et al. (2011) Functional and epigenetic studies reveal multistep differentiation and plasticity of in vitro-generated and in vivo-derived follicular T helper cells. Immunity 35(4):622-632.
39. Cannons JL, Lu KT, Schwartzberg PL (2013) T follicular helper cell diversity and plasticity. Trends Immunol 34(5):200-207.
40. Zhu J, Yamane H, Paul WE (2010) Differentiation of effector CD4 T cell populations. Annu Rev Immunol 28:445-489.
41. Crotty S (2011) Follicular helper CD4 T cells (TFH). Annu Rev Immunol 29:621-663.
42. Bernier A, et al. (2013) Transcriptional profiling reveals molecular signatures associated with HIV permissiveness in Th1Th17 cells and identifies peroxisome proliferator-activated receptor gamma as an intrinsic negative regulator of viral replication. Retrovirology 10:160.
43. Gosselin A, et al. (2010) Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. J Immunol 184(3):1604-1616.
44. Weaver CT, Elson CO, Fouser LA, Kolls JK (2013) The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol 8:477-512.
45. Evans CM, Jenner RG (2013) Transcription factor interplay in T helper cell differentiation. Brief Funct Genomics 12(6):499-511.
46. Staprans SI, et al. (2004) Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci USA 101(35):13026-13031.
47. Chahroudi A, et al. (2014) Target cell availability, rather than breast milk factors, dictates mother-to-infant transmission of SIV in sooty mangabeys and rhesus macaques. PLoS Pathog 10(3):e1003958.
48. Duerr A, et al.; Step/HVTN 504 Study Team (2012) Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 206(2):258-266.
49. Zak DE, et al. (2012) Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA 109(50):E3503-E3512.
50. Benlahrech A, et al. (2009) Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci USA 106(47):19940-19945.
51. Uyeki TM (2014) Preventing and controlling influenza with available interventions. N Engl J Med 370(9):789-791.
52. Tricco AC, et al. (2013) Comparing influenza vaccine efficacy against mismatched and matched strains: A systematic review and meta-analysis. BMC Med 11:153.
53. Flannery B, et al.; Centers for Disease Control and Prevention (CDC) (2014) Interim estimates of 2013-14 seasonal influenza vaccine effectiveness-United States, February 2014. MMWR Morb Mortal Wkly Rep 63(7):137-142.
54. Chung AW, et al. (2014) Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med 6(228):228ra238.
55. Amanna IJ, Carlson NE, Slifka MK (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357(19):1903-1915.
56. Amanna IJ, Slifka MK (2010) Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 236:125-138.
57. Hammarlund E, et al. (2003) Duration of antiviral immunity after smallpox vaccination. Nat Med 9(9):1131-1137.
58. Crotty S, et al. (2003) Cutting edge: Long-term B cell memory in humans after smallpox vaccination. J Immunol 171(10):4969-4973.
59. Hens N, Habteab Ghebretinsae A, Hardt K, Van Damme P, Van Herck K (2014) Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine 32(13):1507-1513.
60. David MP, et al. (2009) Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol 115(3, Suppl):S1-S6.
61. Fraser C, et al. (2007) Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 25(21):4324-4333.
62. Ault KA (2007) Long-term efficacy of human papillomavirus vaccination. Gynecol Oncol 107(2, Suppl 1):S27-S30.
63. Nossal GJ, Makela O (1962) Autoradiographic studies on the immune response. I. The kinetics of plasma cell proliferation. J Exp Med 115:209-230.
64. Makela O, Nossal GJ (1962) Autoradiographic studies on the immune response. II. DNA synthesis amongst single antibodyproducing cells. J Exp Med 115:231-244.
65. Cooper EH (1961) Production of lymphocytes and plasma cells in the rat following immunization with human serum albumin. Immunology 4:219-231.
66. Schooley JC (1961) Autoradiographic observations of plasma cell formation. J Immunol 86:331-337.
67. Andraud M, et al. (2012) Living on three time scales: The dynamics of plasma cell and antibody populations illustrated for hepatitis a virus. PLOS Comput Biol 8(3):e1002418.
68. Taillardet M, et al. (2009) The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by longlived plasma cells. Blood 114(20):4432-4440.
69. Allard M, Lebre V, Robine J-M, Calment J, Coupland B (1998) Jeanne Calment: From Van Gog's Time to Ours (Freeman), New York.
70. Miller RA, Harper JM, Dysko RC, Durkee SJ, Austad SN (2002) Longer life spans and delayed maturation in wild-derived mice. Exp Biol Med (Maywood) 227(7):500-508.
71. Mattison JA, et al. (2012) Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 489(7415):318-321.
72. McCormack S, et al. (2000) A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine 18(13):1166-1177.
73. Francis DP, et al. (1998) Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses 14(Suppl 3):S325-S331.
74. Liu P, et al. (2013) Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol 87(14):7828-7836.
75. Pegu P, et al. (2013) Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol 87(3):1708-1719.
76. Zolla-Pazner S, et al. (2013) Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS ONE 8(1):e53629.
77. Jalah R, et al. (2014) DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaques. PLoS ONE 9(3):e91550.
78. Fauci AS, Marovich MA, Dieffenbach CW, Hunter E, Buchbinder SP (2014) Immunology. Immune activation with HIV vaccines. Science 344(6179):49-51.
79. National Institute of Allergy and Infectious Disease, National Institutes of Health (2013) Mini-Summit on Adenovirus Platforms for HIV Vaccines (NIH, Bethesda, MD).
80. Masek-Hammerman K, et al. (2010) Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5. J Virol 84(19):9810-9816.
81. Bukh I, et al. (2014) Increased mucosal CD4+ T cell activation in rhesus macaques following vaccination with an adenoviral vector. J Virol 88(15):8468-8478.
82. DeVico A, et al. (2007) Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci USA 104(44):17477-17482.
83. Fouts TR, et al. (2000) Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J Virol 74(24): 11427-11436.
84. de Souza MS, et al.; Ministry of Public Health-Thai AIDS Vaccine Evaluation Group Collaborators (2012) The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 188(10): 5166-5176.
85. Corey L, et al. (2011) HIV-1 vaccines and adaptive trial designs. Sci Transl Med 3(79):79ps13.
86. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC (2008) Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 14(6):617-621.
87. Morgan C, et al. (2008) The use of nonhuman primate models in HIV vaccine development. PLoS Med 5(8):e173.
88. Genescà M, Miller CJ (2010) Use of nonhuman primate models to develop mucosal AIDS vaccines. Curr HIV/AIDS Rep 7(1):19-27.
89. Staprans SI, Feinberg MB, Shiver JW, Casimiro DR (2010) Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective. Curr Opin HIV AIDS 5(5):377-385.
90. Lifson JD, Haigwood NL (2012) Lessons in nonhuman primate models for AIDS vaccine research: From minefields to milestones. Cold Spring Harb Perspect Med 2(6):a007310.
91. Van Rompay KK (2012) The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies. AIDS Res Hum Retroviruses 28(1):16-35.
92. Evans DT, Silvestri G (2013) Nonhuman primate models in AIDS research. Curr Opin HIV AIDS 8(4):255-261.
93. McChesney MB, Miller CJ (2013) New directions for HIV vaccine development from animal models. Curr Opin HIV AIDS 8(5):376-381.
94. Shiver JW, et al. (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415(6869):331-335.
95. Casimiro DR, et al. (2005) Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 79(24):15547-15555.
96. Wilson NA, et al. (2009) Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol 83(13):6508-6521.
97. Qureshi H, et al. (2012) Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J Virol 86(4):2239-2250.
98. Tenbusch M, et al. (2012) Risk of immunodeficiency virus infection may increase with vaccine-induced immune response. J Virol 86(19):10533-10539.
99. Wilson NA, et al. (2006) Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 80(12):5875-5885.
100. Mascola JR, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6(2):207-210.
101. Mascola JR, et al. (1999) Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73(5):4009-4018.
102. Baba TW, et al. (2000) Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simianhuman immunodeficiency virus infection. Nat Med 6(2):200-206.
103. Parren PW, et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75(17):8340-8347.
104. Barnett SW, et al. (2008) Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 22(3):339-348.
105. Barnett SW, et al. (2010) Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol 84(12): 5975-5985.
106. Xu R, et al. (2006) Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. Virology 349(2):276-289.
107. Siliciano RF, et al. (1988) Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: Effect of HIV sequence variation and a mechanism for CD4+ cell depletion. Cell 54(4):561-575.
108. Norris PJ, et al. (2004) Beyond help: Direct effector functions of human immunodeficiency virus type 1-specific CD4(+) T cells. J Virol 78(16):8844-8851.
109. Schieffer M, et al. (2014) Induction of Gag-specific CD4 T cell responses during acute HIV infection is associated with improved viral control. J Virol 88(13):7357-66.